The microtubule-associated protein tau and amyloid-b (Ab) are key players in Alzheimer's disease (AD). Ab and tau are linked in a molecular pathway at the post-synapse with tau-dependent synaptic dysfunction being a major pathomechanism in AD. Recent work on site-specific modification of dendritic and more specifically post-synaptic tau has revealed new endogenous functions of tau that limits synaptic Ab toxicity. Thus, molecular studies opened a new perspective on tau, placing it at the center of neurotoxic and neuroprotective signaling at the post-synapse. Here, we review recent advances on tau in the dendritic compartments, with implications for understanding and treatment of AD and related neurological conditions.
Introduction
The neuropathological hallmarks of Alzheimer's disease (AD) are the presence of extracellular amyloid-b (Ab) plaques and intraneuronal neurofibrillary tangles (NFTs), containing aggregates of the microtubule-associated protein tau (Ittner and Gö tz, 2011; Scheltens et al., 2016) . Tau has been implicated in multiple neurodegenerative disorders, leading to the coining of the term ''tauopathies,'' with AD being most prevalent, but including a range of frontotemporal dementias (FTDs) with isolated tau pathology in the absence of Ab deposition (Ballatore et al., 2007; Goedert et al., 2012; Ittner and Gö tz, 2011) . Furthermore, tau pathology has been observed in Parkinson's disease (PD) (Irwin et al., 2013) . Interestingly, it is the tau but not Ab pathology that correlates with cognitive impairment in AD (reviewed in Serrano-Pozo et al., 2011) . Intensive research focusing on the role of tau in disease has provided insight into a range of pathomechanisms involving tau in different neuronal compartments, opening new avenues to targeting tau for the treatment of AD and FTD (Polanco et al., 2018) . This Review will focus on a more recently discovered aspect of tau in AD, namely its role in mediating neurotoxicity in the dendrite and its specialized post-synaptic compartment of neurons.
A Brief Introduction of Tau
The microtubule-associated protein tau is encoded by the MAPT gene on human chromosome 17 (17q21.31) and expressed in the mature brain in 6 alternatively spliced isoforms, harboring 0, 1, or 2 amino (N)-terminal inserts (0N, 1N, or 2N) and 3 or 4 repeats (3R or 4R) in the carboxy-terminal part of the protein ( Figure 1A ). During development, only 3R isoforms of tau are expressed (reviewed in Caillet-Boudin et al., 2015; D'Souza and Schellenberg, 2005) . The primary sequence of tau is divided in an N-terminal half, referred to as ''projection domain,'' followed by a Prolinerich region ( Figure 1A ). The C-terminal half of tau harbors the microtubule-binding repeats (MTRs) that are the defining features of the members of the microtubule-associated protein (MAP) family (reviewed in Dehmelt and Halpain, 2005) . They are followed by a largely uncharacterized C-terminal tail. Tau is a substrate for a large number of kinases and contains 77 potential Serine/Threonine and 4 Tyrosine phosphorylation sites clustered in the Proline-rich region and the tail domain adjacent to the MTRs (reviewed in Noble et al., 2013) . In addition to phosphorylation, several other secondary modifications to tau and protease-mediated cleavage have been reported and may contribute differentially to physiological functions of tau and disease ( Figure 1A ) . Phosphorylation of different residues compromises tau's binding to microtubules (MT), suggesting regulation of tau functions by kinase/phosphatase activity (Ding et al., 2006; Drewes et al., 1995; Schwalbe et al., 2013) . In AD and FTDs, tau becomes progressively phosphorylated at multiple sites (= hyperphosphorylated). Together with changes in local environment, deficits in molecular chaperones, and degradation, this makes it prone to oligomerization and paired helical filament (PHF) formation, which eventually leads to neurofibrillary tangles (NFT) ( Figure 1B ) (Spires-Jones et al., 2009) . While tau was initially described as a neuronal protein that is enriched in the axon (Hirokawa et al., 1996; Kanai and Hirokawa, 1995) , its presence within dendrites and at the post-synapse, both under physiological and pathological conditions, has only been discovered more recently (Ittner et al., 2010) .
Synaptic Dysfunction in AD
The neuronal synapse is the molecular coder-decoder unit between neurons of the central nervous system (CNS). Three specialized compartments constitute synapses; first, the presynapse formed by axon terminals of the ''coder'' neuron is specialized in coordinated release of neurotransmitters (reviewed in S€ udhof, 2013) . Second, the post-synapse is located on dendritic shafts or specialized protrusions, called spines, of the ''decoder'' neuron. The receptor-rich membrane portion of the post-synapse is referred to as post-synaptic density (PSD), harboring an array of scaffolding and signaling proteins linked to surface receptors (reviewed in Sheng and Kim, 2011) . Finally, the synaptic cleft is located between the pre-and post-synapse (Kaeser and Regehr, 2014; S€ udhof, 2013) . Furthermore, other neural cell types such as astrocytes and microglia contribute to synaptic maintenance and function (Kettenmann et al., 2013) .
Synaptic dysfunction contributes to several forms of dementia and neurodegeneration, including AD, highlighting the essential role of the neuronal synapse for healthy brain function (Mucke and Selkoe, 2012; Palop and Mucke, 2010; Sheng et al., 2012) . Accordingly, synaptic loss has been described as an early morphological change in human post-mortem brains from AD patients (reviewed in Forner et al., 2017; Scheff et al., 2014) . Oligomeric forms of Ab can induce synaptic loss in neurons in vitro and in vivo (Blurton-Jones and Laferla, 2006; Ittner and Gö tz, 2011; Mucke and Selkoe, 2012) , indicating that Ab is a driver of synaptic dysfunction in AD. Functionally, Ab-induced synaptic loss contributes to dysfunction of neuronal networks in AD, presenting with hypersynchronicity/epileptiform discharges during electroencephalographic recordings in AD patients (reviewed in Palop and Mucke, 2010) . Similarly, synaptic loss and neuronal network aberrations were recapitulated in human Ab-precursor protein (APP)-transgenic mouse models of AD (Cayzac et al., 2015; Ittner et al., 2014; Palop et al., 2007; Roberson et al., 2011; Si sková et al., 2014; Verret et al., 2012) . These synaptic and network deficits induced by Ab were intimately connected A B Figure 1 . Tau (A) The microtubule-associated protein tau is encoded by the MAPT gene and expressed as 6 alternatively spliced isoforms, harboring 0, 1, or 2 amino (N)-terminal inserts (0N, 1N, or 2N ) and 3 or 4 repeats (3R or 4R) in the carboxy-terminal part of the protein. The primary sequence of tau comprises an N-terminal half, referred to as ''projection domain,'' followed by a Proline-rich region. The C-terminal contains the microtubule-binding repeats (MTRs) and is followed by a largely uncharacterized C-terminal tail. Tau is a substrate for a large number of kinases and contains potential 77 Serine/Threonine (positions indicated by blue lines) and 4 Tyrosine phosphorylation sites (dark red lines). Other secondary modifications (e.g., acetylation, ubiquitination) and protease-mediated truncation have been reported and may contribute differentially to disease and to physiological functions of tau. (B) Kinase/phosphatase activities modulate tau phosphorylation, thereby altering tau's binding to microtubules (MT). In AD and FTDs, tau becomes progressively phosphorylated at multiple sites. This ''hyperphosphorylated'' state of tau together with alterations in local environment, chaperone function, cell stress, and other factors make it prone to oligomerization and paired helical filament (PHF) formation, eventually leading to neurofibrillary tangles (NFT).
to tau, since reducing endogenous tau levels in Ab-forming AD mouse models prevented dysfunction mediated by molecular changes at the post-synapses (Bi et al., 2017; Ittner et al., 2010; Roberson et al., 2007 Roberson et al., , 2011 . In contrast, increasing tau levels by expression of human tau in amyloidosis mouse models increased synaptic loss and memory impairment (Chabrier et al., 2014; Ittner et al., 2010) . Taken together, these findings have suggested a ''toxic gain-of-function'' hypothesis for tau in AD pathogenesis (Ittner and Gö tz, 2011) . Experimental therapeutic approaches targeting transgenic human tau successfully reduced synaptic dysfunction, cognitive deficits, and histopathological abnormalities, either by antibody-mediated (Boutajangout et al., 2010; Castillo-Carranza et al., 2015; Ittner et al., 2015; Yanamandra et al., 2013) or anti-sense oligonucleotide (ASO)-mediated tau reduction (DeVos et al., 2017) in pre-clinical animal models of AD and tauopathy.
Despite the evidence of a pathological gain of function of tau in disease, possible loss of physiological functions of tau, in particular at the post-synapse, remain unclear. Genetic targeting of the tau-encoding Mapt gene in mice has been achieved independently, yet surprisingly, did not reveal major indispensable functions of tau, including in cognition (Dawson et al., 2001; Harada et al., 1994; Tan et al., 2018; Terwel et al., 2005; Tucker et al., 2001 ). Furthermore, findings from different tau-deficient mouse strains are conflicting, with studies suggesting that tau is required for maintenance of dopaminergic neurons (Lei et al., 2012 (Lei et al., , 2014 , while other studies show that it is dispensable for maintenance of these cells (Morris et al., 2013; van Hummel et al., 2016) . Recent findings of compromised synaptic plasticity and altered metabolism in tau-deficient mice illustrate possible loss-of-function tau early in disease (Ahmed et al., 2014; Marciniak et al., 2017) when normal tau may be sequestered into newly formed deposits. To this end, it is critically important to understand the physiological functions of tau to gain further insight into molecular mechanisms during neurodegeneration.
Polarized Neuronal Distribution of Tau
Early studies have shown that tau is predominantly localized to axons due to higher affinity of tau to microtubules in axons than dendrites or soma of healthy neurons (Hirokawa et al., 1996; Kanai and Hirokawa, 1995) . Understanding the molecular mechanisms that determine sorting of tau to axons is crucial, since these determine whether and how much tau is available to other compartments within neurons (Figure 2A ). Despite high axonal tau levels, tau abundance within the axonal presynaptic terminal is low.
A diffusion barrier for axonal proteins in cultured neurons coincides with the axon initial segment (AIS) (Rasband, 2010; Winckler et al., 1999) . The AIS was shown to limit the amount of tau relocalizing from axon to soma (Li et al., 2011) . This retrograde diffusional restriction of tau may be governed by several protein-protein interactions of tau with AIS complexes (such as ankyrinG/EB1, GSK3b) (Zempel et al., 2017) . Furthermore, post-translational modifications may affect axonal enrichment of tau as acetylation regulates tau sorting at the AIS in cultured neurons (Tsushima et al., 2015) . To this end, the AIS appears to be a significant barrier to retrograde tau diffusion from the axon into the soma. Whether phosphorylation of tau compromises the restrictive role of the AIS on tau sorting and would therefore allow retrograde diffusion-consistent with the idea that hyperphosphorylated tau re-distributes from axons to the somato-dendritic compartment-remains unknown. Interestingly, hyperphosphorylated tau in primary cultured neurons and mutant tau transgenic mice induced a distal shift of the AIS, which was associated with reduced excitability of neurons (Hatch et al., 2017) . Furthermore, oligomeric Ab disrupts integrity of the AIS (Marin et al., 2016; Tsushima et al., 2015) , contributing to the loss of tau polarization seen in AD neurons.
An alternative mechanism of axonal tau enrichment has been proposed with the identification of its interaction with Annexin A2 in the distal part of the axon, providing a sink for directional distribution of tau (Gauthier-Kemper et al., 2011) . Interestingly, Annexin A5, another member of the Annexin family, also binds to tau (Stefanoska et al., 2018) . It remains to be shown whether similar interaction partners of tau reside in other neuronal compartments, including the post-synapse, to provide additional local sinks.
Taken together, different mechanisms may orchestrate the predominantly axonal localization of tau, thereby indirectly affecting and limiting its availability to other neuronal compartments such as the soma, dendrites, and, in particular, the post-synapse. Therefore, it is even more intriguing that the limited amounts of tau in the latter compartments may contribute to important and specific processes, including in AD pathogenesis.
Regulatory Pathways of Dendritic/Post-synaptic Tau Localization Localization of tau to dendrites is a long-standing observation in AD and FTD; hyperphosphorylated tau accumulates in the soma and dendrites, leading to the typical flame-shaped appearance of NFTs (Bancher et al., 1987) . Therefore, the histopathological presence of tau in dendritic compartments in AD suggested early on that tau in this compartment is relevant to human disease condition. Importantly, oligomeric Ab and amyloid accumulation increase mislocalization of tau to the somato-dendritic compartment in AD mouse models (Gö tz et al., 2001; Lewis et al., 2001) . Reflecting the histopathological findings in AD, overexpression of non-mutant and mutant tau in cultured neurons and in transgenic mice results in localization of exogenous tau in the somato-dendritic compartment, in addition to axonal tau (Hoffmann et al., 2013; Jaworski et al., 2011; Gö tz et al., 1995) . Increased post-synaptic tau levels were linked to spine loss in P301S transgenic mice (Hoffmann et al., 2013; Jaworski et al., 2011) . This may contribute to increased sensitivity to toxic signaling in mutant tau transgenic mice (García-Cabrero et al., 2013; Liu et al., 2017) . However, pathological secondary modification (i.e., hyperphosphorylation) and/or non-physiological high levels of tau due to overexpression might have been the driving forces of dendritic localization here, providing little insight into non-axonal distribution of endogenous tau. The concept of post-synaptic localization of endogenous tau was introduced when it was shown that endogenous tau localizes to dendrites/ post-synapses under physiological conditions and contributes to post-synaptic signaling in human APP-expressing AD mouse models (Ittner et al., 2010) . Specifically, this study used expression of a dominant-negative tau variant and tau depletion in mice to reveal how endogenous tau mediates post-synaptic signals in Ab toxicity. Subsequent studies confirmed that endogenous tau localizes to dendrites and post-synapses in rodent neurons, using immune-labeling, synaptosomal fractionation, and ultrastructural analysis approaches (Ittner et al., 2010 Kimura et al., 2013; Mondragó n-Rodríguez et al., 2012; Swanson et al., 2017; Zempel et al., 2013) . Furthermore, mice genetically engineered to express endogenous tau with a C-terminally fused mEOS2 fluorescent reporter showed that endogenous murine tau localizes to dendritic spines (Xia et al., 2016) . In summary, endogenous tau localizes to dendrites and the post-synapse under physiological conditions, in addition to its predominant enrichment in axons ( Figure 2A ). This raised the question, which determinants govern dendritic/ post-synaptic localization of tau. Tau binds to components of the post-synaptic density (PSD) ( Figure 2B , a) including scaffolding proteins and receptor complexes. Both intrinsic features of tau and extrinsic mechanisms may contribute to its dendritic and post-synaptic recruitment. Intrinsic properties of tau include isoform composition, since 2N tau showed a higher propensity for sorting into the somato-dendritic compartment, as compared to other tau variants (Zempel et al., 2017) . Furthermore, a truncated tau variant lacking the MTRs after amino acid 255 did not distribute to dendritic compartments in cultured neurons and in transgenic mouse brains (Ittner et al., 2010) . Hence, tau localization from the soma to the dendrite ( Figure 2B , b) and into the post-synapse ( Figure 2B , c) depends on binding to microtubules, or to yet to be identified MTR interaction partner(s). Whether 3R and 4R tau isoform differentially localize to dendrites/post-synapses remains to be addressed experimentally. This is of importance as isoforms of tau are differentially modified in AD (Singh et al., 1996) and have different effects on AD pathology (Bué e et al., 2000) . To this end, a comprehensive overview of which primary sequence components may further contribute to the dendritic/post-synaptic localization, particularly of endogenous tau under physiological conditions, is required. In addition to post-translational localization of tau, the protein might be produced locally at post-synapses with recruitment of tau messenger RNA (mRNA) and localized translation ( Figure 2B , d) (Kobayashi et al., 2017; Li and Gö tz, 2017) . This process may directly contribute to increased dendritic tau levels in AD, as suggested by the finding of increased dendritic tau translation induced by Ab in a manner dependent on Src kinase Fyn (Li and Gö tz, 2017) .
Extrinsic factors and extracellular signals regulate dendritic/ post-synaptic localization. Tau localization to dendrites and post-synapses may be connected to synaptic plasticity. Accordingly, long-term potentiation (LTP), a plasticity mechanism critical for memory formation (reviewed in Bannerman et al., 2014) , increased post-synaptic levels of tau ( Figure 2B , f) (Frandemiche et al., 2014) . Engagement and redistribution of postsynaptic glutamate receptors is critical in synaptic plasticity (reviewed in (Paoletti et al., 2013) . Activation of synaptic glutamate receptors in cultured neurons induced translocation of tau from dendritic shafts into post-synaptic densities together with Fyn kinase ( Figure 2B , e) (Frandemiche et al., 2014; Ittner et al., 2010) . This post-synaptic localization of Fyn has been shown to be tau dependent (Ittner et al., 2010) .
Extracellular signals can affect tau localization in the brain. Increased basal levels of glucocorticoid (GC) are associated with cognitive impairment in AD (Huang et al., 2009) . Chronic stress and glucocorticoid treatment increase tau localization to soma and dendrites (Lopes et al., 2016; Sotiropoulos et al., 2011) . Similarly, exposure to oligomeric Ab promotes levels of tau in dendrites ( Figure 2B , e), contributing to the increased levels of tau in this compartment in AD (Zempel et al., 2010) . How tau recruitment to the dendritic compartment is mechanistically regulated in response to such stress stimuli remains to be shown. In addition, neuroinflammation with microglial recruitment and astrocytic activation is a prominent feature of AD brain tissue (Birch et al., 2014) . Whether microglia or astrocytes directly affect post-synaptic tau remains to be determined. Taken together, intrinsic tau properties and extracellular signals converging on tau form a complex regulatory network of dendritic tau localization.
Post-synaptic Functions of Tau
While protein localization may not necessarily predict functional importance within the respective compartment, mechanistic studies of tau within the dendritic/post-synaptic compartment have delineated specific roles of tau at these sites. Evidence sparking the idea that tau may be involved in post-synaptic processes in AD came from studies in primary neurons and APP transgenic mouse models, which showed that Ab toxicity depends on the presence of endogenous murine tau (Ittner et al., 2010; Rapoport et al., 2002; Roberson et al., 2007) . Previous work had shown that toxic Ab oligomers can bind and induce signaling via post-synaptic receptors, including N-methyl-Daspartate receptors (NMDARs), mediating a type of neuronal toxicity reminiscent of glutamate-mediated excitotoxicity (reviewed in Aarts and Tymianski, 2004) . Accordingly, Memantine, a weak NMDAR antagonist and FDA-approved drug for AD treatment, possibly acts via preventing Ab-type excitotoxicity (Danysz and Parsons, 2012). Engagement of NMDARs results in downstream signaling that, under physiological conditions, contributes to adaptive neuronal responses including LTP formation and synaptic strengthening (Paoletti et al., 2013) . However, in excitotoxicity NMDARs contribute to divergent and convergent toxic signals. Post-synaptic Tau Mediates Excitotoxicity A key to the engagement of post-synaptic toxic signaling pathways in Ab-type excitotoxicity is the tau-dependent recruitment of the Src-family tyrosine kinase Fyn to post-synaptic NMDAR complexes (Ittner et al., 2010) . In facilitating this recruitment, tau interacts with Fyn via Proline-X-X-Proline (PXXP) motifs in the Proline-rich region of tau (Ittner et al., 2010; Lau et al., 2016; Lee et al., 1998) . At the post-synapse, the tau/Fyn complex interacts with the PDZ (post-synaptic density, discs-large, zona occludens protein-1) domain protein PSD-95 (Ittner et al., 2010; Lopes et al., 2016; Mondragó n-Rodríguez et al., 2012) , a key scaffolding protein for post-synaptic receptors (Kim and Sheng, 2004) . While tau is essential for recruiting Fyn to the PSD-95 complex, it is the localized activity of Fyn that is critical for NMDAR-mediated excitotoxicity ( Figure 3A ) (Ittner et al., 2010; Knox et al., 2014; Miyamoto et al., 2017) . Several phosphorylation targets of Fyn may act in concert to regulate NMDAR-mediated excitotoxicity. Accordingly, Fyn phosphorylates the post-synaptic NMDAR subunit 2B (NR2B) at tyrosine-1472 of its cytosolic C-terminus, which enhances the interaction between NR2B and PSD-95 and thereby enables engagement of toxic downstream signaling pathways in neurons (Rong et al., 2001 ). Fyn-dependent NR2B phosphorylation has also been implicated in a range of acute neuronal conditions; for example, it was shown to promote neuronal injury in focal brain ischemia (Knox et al., 2014; Zhang et al., 2014a) and persistency of neuropathic pain (Abe et al., 2005) . Interestingly, chronic stress exposure results in increased formation of postsynaptic complexes of PSD-95, tau and Fyn (Lopes et al., 2016) , providing a potential explanation how psychogenic chronic stress and other factors that use stress pathways can affect tau-dependent toxicity. Finally, Fyn can phosphorylate tau at tyrosine-18 (Miyamoto et al., 2017) . This phosphorylation of tau is important for the interaction of tau with Fyn (Bhaskar et al., 2005) , adding another means of regulating PSD-95/tau/ Fyn complexes. Tau mediates neurotoxic signals downstream of post-synaptic NMDARs in disease conditions that are not induced by Ab. Absence of tau is protective against induced excitotoxic seizures (Holth et al., 2013; Ittner et al., 2010; Roberson et al., 2007) and in models of stroke-associated excitotoxicity (Bi et al., 2017; Tuo et al., 2017) . In stroke and seizure models, tau knockout mice showed blunted NMDAR-mediated activation of extracellular signal-regulated kinase (ERK). For comparison, ERK was rapidly activated upon stroke and seizure induction in naive mice or direct stimulation of synaptic NMDARs in cultured naive neurons. Here, post-synaptic tau was found to control NMDAR-mediated ERK activation by limiting SynGAP1, a negative regulator of synaptic ERK activation (Komiyama et al., 2002; Rumbaugh et al., 2006) , in PSD-95/tau complexes ( Figure 3B ) (Bi et al., 2017) . It is of note, that SynGAP1 mutations have been associated with impaired cognitive development due to synaptic deficits (Clement et al., 2012) . Furthermore, reduction of tau levels by ASOs is sufficient to protect mice from seizures ( Figure 3C ) (DeVos et al., 2013) . These findings provide further evidence for a (direct) role of tau in organization and composition of post-synaptic complexes involving NMDAR signaling, in particular during excitotoxicity.
Further NMDAR-mediated mechanisms involving tau have been suggested for the tau kinase GSK3b; Ab induced tau phosphorylation by GSK3b and neuronal toxicity in an NMDARdependent manner in slice cultures using GFP-labeled tau (Tackenberg and Brandt, 2009 ). The NR2B-containing NMDARs were critical to activate GSK3b and phosphorylate tau upon Ab exposure (Tackenberg et al., 2013) . Incubating slices with NMDAR inhibitors, however, did not distinguish between synaptic and extra-synaptic NMDARs. The latter affect excitotoxic signaling upon generalized receptor activation in vitro (Hardingham and Bading, 2010) . To this end, in vivo confirmation of a post-synaptic GSK3b/tau axis in Ab-type excitotoxicity is pending.
Thus, downstream factors of tau at the post-synapse and in complex with PSD-95 may include Fyn (Ittner et al., 2010) , ERK (Bi et al., 2017) , and GSK3b (Tackenberg et al., 2013) . The entirety of downstream factors of tau in this context is a matter of ongoing research and may reveal additional drug targets for treatment of excitotoxic neuronal damage in AD. Dendritic Tau in Synaptic Plasticity NMDAR signaling at the post-synapse regulates synaptic plasticity, affecting LTP and long-term depression (LTD) through alterations in localization of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors at post-synaptic membranes (Paoletti et al., 2013) . The relation of tau to synaptic plasticity is a matter of current investigation. Recent work with tau knockout mice showed no differences in LTP formation (Regan et al., 2015) . In contrast, tau is required for LTD in recordings from brain slices of both mice and rats (Kimura et al., 2013; Marciniak et al., 2017; Regan et al., 2015) . Interestingly, tau reduction in heterozygous tau knockout mice was sufficient to reduce LTD formation to the same extend as in homozygous tau knockout mice, while LTP formation was unaffected by tau reduction and depletion (Kimura et al., 2013) . Furthermore, tau knockout mice showed reduced insulin-induced LTD, possibly regulated by the tumor suppressor inositide phosphatase PTEN (Marciniak et al., 2017) . Notably, LTP, but not LTD, deficits in tau-deficient mice were reported by others (Ahmed et al., 2014) , adding to the list of opposing findings in tau knockout mice. In AD, plasticity may be affected by oligomeric tau, which was shown to impair LTP and memory in mice (Puzzo et al., 2017) , consistent with LTP deficits in mutant tau transgenic mice (Rosenmann et al., 2008) . Dendritic Tau and the Synaptic Cytoskeleton Another functional aspect of dendritic tau relates to its involvement in cytoskleleton-dependent processes that maintain synaptic function. Ab induced dendritic tau accumulation and disruption of the local cytoskeleton (Zempel and Mandelkow, 2012) . In this context, dendritic localization of tubulin-tyrosineligase-like 6 (TTLL6) may contribute to microtubule network destabilization and spine loss in cultured neurons (Zempel and Mandelkow, 2015) . In contrast to murine neurons, tau depletion in the fruit fly Drosophila caused progressive neurodegeneration, likely due to absence of other compensating MAPs (Bolkan and Kretzschmar, 2014) . Neurons cultured from tau-deficient Drosophila showed the requirement of tau for maintenance of mature synapses, independent of axon integrity, but linked to jun N-terminal kinase (JNK) signaling and kinesin-3/microtubule-dependent transport of cargos (Voelzmann et al., 2016) . It is understood that microtubule dynamics contribute to spine morphology and function (Jaworski et al., 2009 ). Whether tau is involved in post-synaptic microtubule dynamics remains to be shown, and future studies are required to understand the molecular processes that link tau and the complex post-synaptic cytoskeleton.
Dendritic Tau in Neuronal Network Function
How tau-dependent effects on synaptic plasticity impact on neuronal physiology at the network level is only beginning to emerge. Under basal conditions, cortical network activity of tau knockout mice assessed by electroencephalography showed spectral waveform distributions analogous to wildtype controls (Bi et al., 2017; Ittner et al., 2016) . However, tau contributes to neuronal circuits under conditions of stress; network aberrations in cortex and hippocampus of Ab-forming APP mouse models (Born et al., 2014; Goutagny et al., 2013; Ittner et al., 2014; Verret et al., 2012) were found to be tau dependent Roberson et al., 2011) , suggesting that synaptic alterations mediated through tau translate to the network level. Mechanistically, Ab-induced network dysfunction in these models involves post-synaptic tau signaling via Fyn (Roberson et al., 2011) , as well as specific modulation of postsynaptic tau complexes . Interestingly, heterozygous tau reduction was sufficient to ablate spontaneous seizure activity, further supporting a generalized mechanism of a subset of tau in hypersynchronous network activities (Gheyara et al., 2014; Holth et al., 2013) . How tau-dependent effects on synaptic plasticity impact on neuronal networks under physiological and pathological conditions is still to be determined.
Taken together, post-synaptic tau affects neuronal functions at multiple levels-the synaptic, the cellular, and the network level. Although the detailed composition of post-synaptic tau complexes is pending, key molecules connected with tau are PSD-95 and NMDARs but may include other receptors (AMPARs [Malinow and Malenka, 2002; Regan et al., 2015] ), membrane proteins (cellular Prion protein PrPc [Larson et al., 2012] ), and intracellular signaling proteins (e.g., Fyn [Ittner et al., 2010] and ERK [Bi et al., 2017] ). Here, deciphering post-synaptic signaling pathways downstream of tau, in particular those that mediate Ab-type excitotoxicity, shall be the major task for future studies, in order to identify novel strategies to treat AD.
Post-translational Modifications of Tau in Post-synaptic Signaling
Tau can undergo extensive posttranslational modification (PTM), including phosphorylation, methylation, acetylation, and ubiquitination . Accordingly, paired helical filamentous tau (PHF-tau) in NFTs is phosphorylated at multiple epitopes by a range of kinases in disease (Hanger et al., 1998; Morishima-Kawashima et al., 1995) . Although hyperphosphorylation is associated with pathological tau, tau's PTMs may serve physiological purposes. Supporting this idea, profiling of PTMs showed a low, but detectable pattern of modifications on up to 63 sites on tau in wild-type mouse brains (Morris et al., 2015) . Although a detailed catalog of PTMs of tau at the post-synapse has to be established, modifications of individual phosphorylation sites have been shown to contribute to tau localization and function at the post-synapse (Figure 4) .
Expression of a phosphorylation-mimicking tau variant with 14 proline-directed phosphorylation sites exchanged to aspartate or glutamate increased localization of tau to dendritic spines in cultured neurons, reducing glutamate receptor trafficking and resulting in synaptic impairments (Hoover et al., 2010; Miller et al., 2014) . Similarly, individual phosphorylation-mimicking variants of T231/S235, S262/S356, or S396/S404 epitopes enhanced localization of tau into dendritic spines in cultured neurons (Xia et al., 2015) . Although these studies used overexpression of tau variants that relate to disease rather than to physiology, they indicated that dendritic and post-synaptic tau distribution are directly affected by phosphorylation. However, use of phosphorylation-mimicking variants may be limited in reflecting actual dynamic phosphorylation of tau at these sites. Engagement of NMDARs enhanced phosphorylation of synaptic tau at sites S199/S202 in hippocampal slices exposed to NMDA (Mondragó n-Rodríguez et al., 2012). Here, tau phosphorylation correlated with concomitantly reduced tau levels in post-synaptic PSD-95 complexes and reduced NMDA-mediated excitability, which suggested that tau phosphorylation may limit neuronal excitation ( Figure 4A ) (Mondragó n-Rodríguez et al., 2012) . Interestingly, this study showed NMDAR-dependent, but also NMDAR-independent, phosphorylation of post-synaptic tau (Mondragó n- Rodríguez et al., 2012) .
Although these studies had suggested that post-synaptic tau is a target of phosphorylation, mechanistic implications of these modifications remain largely unknown. Recently, we described a novel and counter-intuitive role of tau phosphorylation at the post-synapse, which limited Ab toxicity in AD mouse models . Phosphorylation of post-synaptic tau at T205 reduced complexes between PSD-95, tau, and Fyn within the post-synapse , therefore uncoupling NMDARs from excitotoxic downstream signaling factors ( Figure 4B ) (Aarts et al., 2002; Ittner et al., 2010) . This specific phosphorylation of post-synaptic tau at T205 was mediated by p38g, a kinase of the p38 MAP kinase family that localizes exclusively to PSDs in neurons. PSD recruitment of p38g is governed by a unique carboxy-terminal motif that facilitates interaction with PDZ domains of PSD-95 Sabio et al., 2004 ). This motif is not shared with the other three mammalian p38 kinases (p38a, p38b, p38d). Using p38g knockout mice and transgenic mice expressing a constitutive active variant of p38g in neurons, as well as adeno-associated virus (AAV)-mediated delivery of p38g, we showed that p38g limits toxic signals downstream of Ab by phosphorylation of post-synaptic tau specifically at T205. Accordingly, p38g activity protected AD mouse models, improving survival, memory function, and neuronal networks aberrations . Disruption of this pathway by loss of p38g expression in AD brains may thus result in a loss of function of protective effects of tau . Whether p38g activation could also improve symptomatic AD mice, and which upstream signals activate p38g, remains to be shown. Although the specific kinases and the contribution of each site identified as relevant for post-synaptic localization remains to be determined, (C) Engagement of synaptic NMDARs increases activity of GSK3b, which phosphorylates tau at S396. Tau phosphorylated at S396 binds to PICK1, a regulator of AMPA receptors (AMPARs) in synaptic plasticity, resulting in increased internalization of surface AMPAR expressed at the PSD, and thus enhances long-term depression (LTD). Tau acetylation at K274 and K281 regulates long-term potentiation (LTP). Tau acetylation, which is reduced by HDAC6, inhibits the postsynaptic protein KIBRA that facilitates AMPA receptor integration into the PSD during LTP. Thus, tau regulates processes during LTP and AMPAR surface expression in an acetylation-dependent manner. a picture is emerging that describes soluble tau and its modification by site-specific phosphorylation as a dynamic component of post-synaptic signaling networks.
Roles of protein phosphatases in dendritic/post-synaptic tau phosphorylation have not been addressed. Protein phosphatase 2A (PP2A), which is an effective tau phosphatase (Sontag et al., 1996) , localizes to dendrites of neurons and its activity decreases upon NMDAR engagement (Fukunaga et al., 2000) . Thus, aberrant engagement of NMDARs by Ab may inhibit PP2A activity contributing to aberrant phosphorylation of dendritic tau (Sontag and Sontag, 2014) . Detailed investigation of PP2A and other tau phosphatases at the post-synapse remains to be done.
Exposure to oligomeric Ab contributes to this increase in tau phosphorylation, promoting toxicity of tau and ultimately increasing NFT formation (Blurton-Jones and Laferla, 2006; Mandelkow and Mandelkow, 2012; Wang and Mandelkow, 2016) . Several kinases may contribute to Ab-induced tau phosphorylation in neurons, some of which can be engaged through post-synaptic signaling pathways. For example, GSK3b was shown to phosphorylate tau in an NMDAR-dependent manner upon exposure of slice cultures to Ab (Tackenberg and Brandt, 2009; Tackenberg et al., 2013) . Interestingly, GSK3b-mediated phosphorylation of tau at S396 regulates the complex of tau with PICK1, enhancing PICK1-mediated AMPAR downregulation during LTD ( Figure 4C ) (Regan et al., 2015) . Furthermore, engagement of tau kinases downstream of Ab is concomitant with tau resorting to the somatodendritic compartment (Zempel et al., 2010) . Tau may then become a substrate for additional kinases within this compartment, contributing to a hyperphosphorylated state of tau. However, little is known about compartmental engagement of specific tau kinases upon Ab exposure and other conditions.
In addition to phosphorylation, other PTMs may influence tau functions at post-synapses. Lysine-directed tau acetylation was shown at all stages of AD, with an increase at early Braak stages (Min et al., 2010) . Acetylated tau contributes to tau aggregation (Cohen et al., 2011; Cook et al., 2014) . Mice expressing acetylation-mimicking K174Q tau variant show lower hippocampal volumes and impaired spatial learning, suggesting that acetylation contributes to cognitive deficits and neurodegeneration (Min et al., 2015) . Using live cell imaging in cultured neurons, a recent study suggested that tau acetylation promotes somatodendritic tau localization . Exposure of cultured neurons to oligomeric Ab was shown to impair activity of histone deacetylase 6 (HDAC6) and increased levels of acetylated tau, resulting in loss of tau polarization, suggesting that Ab is upstream of tau acetylation (Tsushima et al., 2015) . Intriguingly, tau possesses acetyltransferase activity (Cohen et al., 2013) . Transgenesis with acetylation-mimicking tau variants impaired hippocampal LTP and reduced levels of post-synaptic Kidney and brain (KIBRA) protein and AMPAR presentation . KIBRA is a known regulator of AMPARs and memory (Makuch et al., 2011) . These results indicate that post-synaptic tau acetylation may be part of an activity-dependent pathway regulating synaptic plasticity and memory. It is noteworthy that KIBRA interacts with PICK1 during AMPAR trafficking (Makuch et al., 2011) . PICK1 is an interaction partner of phosphorylated tau (Regan et al., 2015) , suggesting that post-synaptic signaling can be affected by an interplay of tau phosphorylation and acetylation.
The roles of other lysine-directed PTMs, i.e., methylation and ubiquitination, in tau trafficking to dendrite and post-synapses have not been addressed directly. Methylation and ubiquitination of tau at several lysine residues were found in wild-type mouse brain, indicating a physiological role (Morris et al., 2015) . These mechanisms appear to be dysregulated in disease. Dysfunction of the ubiquitin-proteasome system in neurons was suggested to contribute to accumulation of phosphorylated forms of tau at synapses (Tai et al., 2012) . Furthermore, methylated tau resides in NFTs, suggesting that tau methylation is relevant to disease (Thomas et al., 2012) .
Several lines of evidence suggest that proteolytic modification of tau may be involved in sorting and post-synaptic functions of tau. Caspase-mediated truncation of tau at aspartate-314 contributes to synaptic dysfunction and cognitive impairments in mouse models (Zhao et al., 2016) . Inhibition of caspase-2 or expression of a caspase-resistant tau variant reduced sorting of tau to the dendritic compartment and prevented cognitive impairment in AD mouse models (Zhao et al., 2016) . This study furthermore suggests that truncated tau interacts with and promotes trafficking of full-length tau to the dendritic compartment, where they contribute to synaptic dysfunction. Cleavage by asparagine endopeptidase (AEP) (encoded by the Lgmn gene) was shown to contribute to tau-mediated synaptic dysfunction; AEP is translocated from lysosomes to cytosol in disease conditions (Basurto-Islas et al., 2013) . Synapse loss, LTP impairment, and cognitive deficits were prevented in tau transgenic mice with Lgmn deletion as compared with tau transgenic controls on a wild-type background. Furthermore, deficits in tau transgenic mice were ameliorated by expression of cleavage-resistant transgenic tau with targeted asparagine (N) variants (N255A/ N368A) (Zhang et al., 2014b) . AEP also targets APP processing as g-secretase , making it a promising therapeutic target that may interfere with amyloid and tau toxicity at several levels. Whether protease activity also contributes to physiological functions of tau at the post-synapse remains unknown.
Taken together, post-synaptic tau is a target of PTM. Whether modification occurs strictly within the post-synaptic, the dendritic compartment, or before tau undergoes localization is not clear in all cases, but the general idea is that tau modifications affect its post-synaptic functions. Targeting post-synaptic modifiers of tau may be new therapeutic options for treating taudependent neurological disorders. This will require a detailed understanding of rates and turnover of tau PTMs at the post-synapse and involved factors and their upstream signals.
Post-synaptic Tau and Spreading of Tau Pathology AD brains are characterized by progressive appearance of NFTs in connected brain regions (Braak and Braak, 1995; Scheltens et al., 2016) . This spreading of tau pathology involves mechanisms that follow tracts of neuronal connectivity (Goedert, 2015; Stancu et al., 2015) . The exact molecular mechanisms underlying spreading of tau pathology are unclear but may involve release of soluble or aggregated tau from exosomes (Asai et al., 2015; Chivet et al., 2013) , by exocytosis/secretion or by breakdown of deteriorating neurons (Kanmert et al., 2015) . In addition, it was suggested that synaptic connections are required, as suggested by trans-synaptic transfer of tau molecules in cultured neurons (Dujardin et al., 2014; Takeda et al., 2015; Wang et al., 2017; Wu et al., 2016) . In a model system of neurons cultured at different maturations states in vitro, interneuronal transfer of tau depended on presence of mature synaptic connections, suggesting tau transfer via the synaptic clefts . Transferred tau in this culture system is associated with exosomes, potentially reconciling the mechanisms of interneuronal transmission via synapses with the release of tau within exosomes (Wood, 2015) . Pathological tau appears to gain prion-like seeding properties over wild-type tau (Goedert et al., 2014; Holmes et al., 2014) . Seeds of trans-synaptically transferred tau would make first contact with post-synaptic tau within receiving neurons, raising the intriguing concept that post-synaptic tau is the primary target for prion-like spreading of tau pathology, including possibly localized oligomerization of tau. Consistent with this idea, exposure to extracellular tau promoted recruitment of endogenous tau into dendrites (Swanson et al., 2017) . Other post-synaptic processes may further contribute to trans-synaptic spread of tau pathology; for example, neuronal activity was shown to promote spread of tau pathology in vivo and in vitro (Calafate et al., 2015; Wu et al., 2016) . Similarly, prolonged exposure to Ab promotes tau propagation (Kanmert et al., 2015; Pooler et al., 2015) . Ab toxicity is-at least in part-mediated through post-synaptic receptors and tau (Ittner et al., 2010; Roberson et al., 2007; Tackenberg et al., 2013) . Therefore, induced PTMs of post-synaptic tau may result in oligomerization-prone tau species that could contribute to spreading of tau pathology. Furthermore, levels of pathological tau were increased in both pre-synaptic and post-synaptic compartments from AD brain tissue (Tai et al., 2014) . Recent results from different tauopathy models showed that tau can impair presynaptic functions (Decker et al., 2015; McInnes et al., 2018; Zhou et al., 2017) . Hence, pre-and post-synaptic changes to tau may orchestrate trans-synaptic spreading of tau pathology.
While lowering tau levels protects from Ab-type excitotoxicity (Ittner et al., 2010; Roberson et al., 2007) , reducing exogenous tau levels in tau transgenic mice using antisense oligonucleotides mitigated seeding of tau pathology (DeVos et al., 2017) . Reduction in tau levels may account largely for this effect on seeding by making ''smaller'' tau pools available at the post-synapse to facilitate prion-like spreading of tau pathology. It is important to note a recent study that challenged the idea endogenous tau is required for spreading per se; when human mutant tau was expressed in the entorhinal cortex of tau-deficient mice using AAVs, spread of human tau to neurons of the dentate gyrus still occurred, but misfolding of tau in recipient neurons was reduced . Taken together, a role of post-synaptic tau in spreading of tau pathology is probable, but direct evidence from in vivo models is missing.
Therapeutic Targeting Post-synaptic Tau Mechanisms
Research over the last decade has established the concept of dendritic/post-synaptic tau and its roles in AD and FTD and shed light on new physiological functions of tau. Together with an increasing understanding of molecular mechanisms of postsynaptic tau, the question has emerged whether these molecular mechanisms or post-synaptic tau itself could be targeted therapeutically.
Reducing tau levels has entered a new phase with studies proposing therapeutic avenues; ASOs successfully reduced human tau levels in mutant tau transgenic mice, improving neurodegeneration (DeVos et al., 2017) . This study also showed that ASOs were able to reduce endogenous tau in non-humane primate brain, taking the next step toward translation (DeVos et al., 2017) . Similarly, passive immunization with 2N human tau-specific single chain antibody improved behavioral deficits and reduced tau phosphorylation in human mutant tau transgenic mice (Nisbet et al., 2017) . Combination with ultrasoundmediated blood-brain barrier opening (reviewed in Polanco et al., 2018) achieved intraneuronal accumulation of the single chain antibody. Whether this approach can be used to reduce tau levels awaits confirmation. To this end, it remains to be shown to which degree endogenous tau would have to be reduced to achieve therapeutic effects. The profound protection from excitotoxicity, early mortality, network, and memory deficits in APP transgenic mice on a heterozygous tau knockout background (Ittner et al., 2010; Roberson et al., 2007) , and seizure protection upon tau reduction by ASOs (DeVos et al., 2013) , would suggest that moderate reduction of endogenous tau may suffice. Reducing overall tau levels may, however, have limitations. It could have, for example, adverse effects on physiologic processes since disrupted hippocampal LTD formation was found in heterozygous tau knockout mice (Kimura et al., 2013) . In addition, protective functions of tau may be impaired by generalized reduction of tau levels . While it remains to be shown experimentally to which degree different tau pools in neurons are reduced in heterozygous tau knockout mice or upon partial ASO/antibodymediated reduction of tau, it is reasonable to assume that the remaining tau is directed predominantly to axons and therefore levels of post-synaptic tau may be depleted to a much greater extent, or even completely. Accordingly, moderate therapeutic overall tau reduction may indeed reduce post-synaptic tau (and other non-axonal tau pools) significantly.
Of the molecular targets clustering around post-synaptic tau, Fyn has progressed furthest in clinical translation. Saracatinib, a repurposed Src kinase inhibitor with broad specificity and previously developed for cancer treatment, was tested for safety and CNS availability in human patients (Nygaard et al., 2015) . This compound is now in a placebo-controlled phase 2 clinical trial for mild AD, testing the concept from preclinical studies that Fyn is a mediator of Ab toxicity at the post-synapse (Chin et al., 2005; Ittner et al., 2010; Um et al., 2012) . A range of new molecular targets related to dendritic and post-synaptic tau have recently emerged and await therapeutic exploration (Table 1) . These include GSK3b (Lovestone et al., 2015) , TTLL6 (Zempel et al., 2013) , p38g , SynGAP1 (Bi et al., 2017) , and tau acetylation (Min et al., 2015) . However, focusing on a specific neuronal compartment imposes additional challenges to CNS drug development apart from the general difficulty to achieve blood-brain barrier passage. Targeting factors in NMDAR downstream signaling appears feasible with proof-of-principle evidence from pre-clinical brain ischemia (Cao et al., 2005) , stroke (Aarts et al., 2002) , and AD rodent models (Ittner et al., 2010) . Identification of disease-limiting functions of post-synaptic tau highlight the importance of obtaining a comprehensive understanding of post-synaptic tau in order to develop targeted therapies and avoid side effects.
The current focus on targeting dendritic tau and its associated pathways is on neurodegenerative diseases, and in particular AD. However, pre-clinical studies in different disease models would suggest that efficient tau-targeted therapies could have much broader implications, including for epileptic seizures (DeVos et al., 2013; Gheyara et al., 2014; Ittner et al., 2010; Roberson et al., 2007) , stroke (Bi et al., 2017; Tuo et al., 2017) , traumatic brain injury , pain (Sotiropoulos et al., 2014) , and stress (Lopes et al., 2016) . However, targeting tau would require reliable diagnosis of underlying conditions; reducing tau increased disease severity and axonal loss in an induced experimental autoimmune encephalomyelitis model (Weinger et al., 2012) . Taken together, targeting post-synaptic tau and mechanisms governed by tau hold promise, but tailored drug development remains challenging.
Conclusion
The recognition of tau as a dendritic and post-synaptic protein, under pathological as well as physiological conditions, has changed research into tau's role in AD pathology. An abundance of specific functions of tau in this compartment is emerging, depicting a complex network of post-synaptic pathomechanisms. Merging current ideas on pathological tau in the post-synapse, pre-synapse, tau spreading, and during tangle formation starts to reveal a concise picture of how tau drives the progression of AD.
Key questions on the role of dendritic and post-synaptic tau remain. These include the following:
(1) Understanding the physiologic function of tau at the postsynapse to elucidate potential loss-of-function effects of tau in AD. (2) Providing a comprehensive map of tau interactions and PTMs in the post-synaptic and dendritic compartment in AD and under healthy conditions. This will likely reveal new druggable targets for the treatment of tauopathies. Genome-editing will allow evaluating the role of individual sites, domains, and targets in vivo. (3) Addressing the role of tau in post-synaptic cytoskeletal dynamics, using advanced imaging together with genetic models. (4) Identifying the signals that drive localization of tau to the post-synapse under physiological conditions and in disease. (5) In regards to reducing tau levels therapeutically, defining the pools of tau that have to be reduced to achieve therapeutic effects is required, but it is necessary to keep in mind that different pools of tau in different cellular compartments may confer unwanted long-term effects if depleted.
Finally, in our opinion, the post-synapse may be the site where tau pathology is initiated as a result of exposure to toxic amounts and/or species of Ab. Site-specific phosphorylation of post-synaptic tau at T205 may initially increase in order to protect neurons from Ab toxicity . But when disease progresses, T205-phosphorylated tau that has dissociated from the PSD could become a substrate for other tau kinases, Summary of approaches based on mechanistic concepts that involve post-synaptic mechanisms linked to tau.
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Neuron Review eventually resulting in increased tau phosphorylation at multiple sites. Hyperphosphorylated tau could then spread first within the affected neurons from the post-synapse via dendrites to the soma and eventually via axonal connections to other neurons.
